EC Number   |
Disease |
PubMed ID  |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.24.84 | Carcinoma |
10373325 |
Identification and chromosomal location of two human genes encoding enzymes potentially involved in proteolytic maturation of farnesylated proteins. |
ongoing research
unassigned |
1
0 |
| 3.4.24.84 | Lymphoma |
10373325 |
Identification and chromosomal location of two human genes encoding enzymes potentially involved in proteolytic maturation of farnesylated proteins. |
ongoing research
unassigned |
1
0 |
| 3.4.24.84 | Muscle Weakness |
12235369 |
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. |
causal interaction
ongoing research
unassigned |
4
2
0 |
| 3.4.24.84 | ste24 endopeptidase deficiency |
12235369 |
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. |
causal interaction
ongoing research
unassigned |
4
2
0 |
| 3.4.24.84 | Laminopathies |
15317753 |
Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. |
unassigned |
0 |
| 3.4.24.84 | Progeria |
15479179 |
Hutchinson-Gilford progeria syndrome. |
therapeutic application
unassigned |
2
0 |
| 3.4.24.84 | ste24 endopeptidase deficiency |
15608054 |
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. |
causal interaction
unassigned |
2
0 |
| 3.4.24.84 | Laminopathies |
15843403 |
Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. |
unassigned |
0 |
| 3.4.24.84 | Osteoporosis |
15984427 |
Application of micro-CT assessment of 3-D bone microstructure in preclinical and clinical studies. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
1
1
0 |
| 3.4.24.84 | ste24 endopeptidase deficiency |
15984427 |
Application of micro-CT assessment of 3-D bone microstructure in preclinical and clinical studies. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
1
1
0 |
